TB-500 (Thymosin Beta-4 Fragment)

1. Quick Facts

Category: Regenerative / Tissue Repair Peptide

Risk Level: Moderate

Research Status: Limited Human Research

Administration: Subcutaneous Injection

Typical Frequency: 1–3 Times Weekly

Estimated Half-Life: Approximately 2–3 Days

Primary Research Interest: Tissue Repair / Recovery / Injury Support

Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and regenerative compounds. TB-500 is a biologically active experimental peptide with limited long-term human safety and efficacy data. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

2. Summary

TB-500 is a synthetic peptide fragment derived from Thymosin Beta-4 (Tβ4), a naturally occurring protein involved in cellular migration, tissue repair, wound healing, and inflammatory signaling pathways.

Research and anecdotal interest in TB-500 primarily center around soft-tissue recovery, injury rehabilitation, connective-tissue repair, inflammation modulation, and regenerative medicine applications.

What People Commonly Claim

Accelerated tendon healing
Faster ligament recovery
Improved muscle repair
Reduced inflammation
Better mobility
Whole-body healing effects

What the Literature Actually Shows

TB-500 is a synthetic peptide fragment derived from Thymosin Beta-4.
Research suggests roles in cellular migration, tissue remodeling, wound healing, and inflammatory signaling pathways.
Most evidence comes from animal studies, laboratory research, and Thymosin Beta-4 investigations rather than direct TB-500 clinical trials.
Human evidence remains limited compared with the extensive preclinical literature.
Direct evidence supporting accelerated recovery in humans remains sparse.
Long-term safety and efficacy remain uncertain.

3. TB-500 vs. Thymosin Beta-4

TB-500 and Thymosin Beta-4 (Tβ4) are often discussed as though they are interchangeable compounds, but they are not the same molecule.

Thymosin Beta-4 is a naturally occurring 43-amino-acid protein found throughout the body and has been extensively studied for its roles in wound healing, tissue repair, inflammation modulation, cellular migration, and angiogenesis.

TB-500 is a synthetic peptide fragment derived from a portion of the Thymosin Beta-4 molecule. It was developed as a smaller research compound intended to capture some of the regenerative properties associated with Tβ4.

One of the most important limitations of the literature is that much of the evidence commonly cited in support of TB-500 actually originates from studies involving full-length Thymosin Beta-4 rather than direct TB-500 clinical research.

As a result, researchers should exercise caution when assuming that findings involving Tβ4 necessarily apply equally to TB-500. While the compounds are biologically related, they are not identical, and direct human evidence for TB-500 remains comparatively limited.

4. Reconstitution Guide

Vial Size: 10 mg
Dilutant Type: BAC Water
Amount of Dilutant Added: 2 mL
Final Concentration: 5.00 mg/mL

At this concentration:
• 2 mg = 0.400 mL (40.0 units)
• 5 mg = 1.000 mL (100.0 units)

*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.

5. Route of Administration

TB-500 is most commonly administered as a subcutaneous injectable regenerative peptide.

Primary Route: SubQ Injection
Preferred Timing: Flexible timing depending on injury-recovery protocol
Administration Notes: Loading phases followed by lower-frequency maintenance phases are commonly discussed within experimental protocols.

6. Common Research Protocols

Product Strength: 5.00 mg/mL
Typical Delivered Amount: Loading phase of 2–5 mg three times weekly for 4 weeks, followed by maintenance dosing of 2–5 mg once weekly
Frequency: Loading phase: 3× weekly / Maintenance phase: 1× weekly
Cycle Length: 6–8 weeks on / 8 weeks off, PRN for injury recovery
Special Notes: Much of the rationale behind TB-500 protocols originates from Thymosin Beta-4 biology rather than direct human TB-500 studies. Due to theoretical links involving angiogenesis and tissue-growth signaling, many researchers recommend caution in situations where increased vascular growth may be undesirable.

7. Mechanism of Action

TB-500 is believed to exert many of its effects through pathways involved in actin regulation, cellular movement, tissue remodeling, and inflammatory signaling rather than through traditional endocrine pathways.

Research suggests that these mechanisms may influence tissue repair and recovery processes throughout the body.

Potential downstream effects discussed in the literature include:

Enhanced cellular migration
Improved tissue-remodeling signaling
Potential angiogenesis support
Reduced inflammatory signaling
Improved recovery from soft-tissue injury
Support for wound-healing pathways

8. Potential Benefits

Potential tendon and ligament recovery support
Enhanced soft-tissue repair signaling
Reduced inflammation
Improved recovery from musculoskeletal injury
Potential mobility and flexibility improvements
Support for wound-healing pathways

9. Potential Risks / Side Effects

Moderate

Injection-site irritation
Fatigue
Headaches
Nausea
Theoretical angiogenesis-related concerns
Limited long-term human safety data
Unknown long-term regenerative-signaling effects

10. Half-Life

TB-500 is commonly discussed as having an estimated half-life of approximately 2–3 days.

This relatively long duration compared with many other peptides contributes to its popularity in lower-frequency experimental protocols.

11. Storage Information

Store refrigerated before and after reconstitution
Protect from direct light exposure
Avoid repeated freeze-thaw cycles
Maintain sterile handling practices during preparation

12. Contraindications / Warnings

Active malignancy or conditions where increased angiogenesis may be undesirable
Pregnancy or breastfeeding
Use alongside experimental angiogenic compounds
Known hypersensitivity to peptide compounds

13. Further Study

14. Research References

PubMed
PubMed Central (PMC)
NIH Publications
Experimental regenerative medicine literature
Thymosin Beta-4 biology research
Tissue-repair and wound-healing journals
Orthopedic regenerative medicine literature

15. Last Reviewed

June 2026